Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

Global cancer-medicine spending reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028; recent FDA approvals and trial results highlight accelerating oncology drug development. Revolution Medicines’ daraxonrasib showed median overall survival of 13.2 months versus 6.7 months with chemotherapy in Phase 3 metastatic pancreatic cancer, while Lilly’s Jaypirca reduced progression-or-death risk by 80% in a CLL trial and Genmab/AbbVie reported a 51% reduction in DLBCL. Oncolytics expects interim data from its randomized colorectal cancer study by year-end; Exelixis’ FDA review was extended three months, with a March 3, 2027 target date. The article discloses the publisher’s prior paid work for, and current share ownership in, Oncolytics.

Analysis

The key dispersion is between commercial validation and binary pipeline optionality. RVMD’s approved RAS therapy raises the value of its broader RAS platform, but launch uptake, tolerability, payer access and duration of benefit—not the approval headline—will determine whether the market can underwrite additional pipeline value. The commercial read-through may also raise the bar for competing RAS and colorectal programs.

ONCY is the highest-risk event exposure: its randomized control arm is the first meaningful test of whether the earlier, non-randomized signal represents incremental benefit over standard therapy. The publisher discloses prior paid work for ONCY and ownership of its shares, so treat its framing and enrollment commentary as promotional until verified in filings and trial updates. An interim response-rate readout can be volatile; randomization, follow-up and biomarker detail matter more than a headline ORR. The proposed pivotal path is not an approval commitment.

For EXEL, the FDA review extension adds time and uncertainty to the colorectal opportunity; a delay is not itself evidence of a negative decision, but updated safety/efficacy requirements can complicate the launch thesis. GMAB/ABBV share potential upside from their lymphoma result, but commercial economics and confirmatory detail are not provided. LLY’s expanded use supports its oncology franchise, while competitive substitution and uptake remain to be established.

Near term, ESMO and year-end data can drive sharp single-name moves. Over 6–18 months, the structural winners will be programs that demonstrate randomized benefit, manageable safety and reproducible access—not simply those in a growing oncology market. Oncology spending forecasts do not guarantee company-level revenue or returns.

Key Decisions for Investors

• Do not chase the sector-wide optimism. For RVMD, wait for post-launch evidence on prescriptions, access and safety before adding on the approval narrative; weakening uptake or restrictive reimbursement would falsify the commercial read-through.
• Treat ONCY as a high-volatility event watch, not a core position on this article. Verify the randomized REO 033 interim dataset, control-arm performance, patient count, follow-up and cash runway; materially weaker response or progression-free survival versus control would undermine the thesis. The publisher’s disclosed conflict raises the verification bar.
• Keep EXEL on regulatory watch rather than assuming the review extension is either benign or adverse. Reassess on FDA communications and the March 2027 decision; further delay, safety concerns or a restrictive label would be negative catalysts.
• For GMAB/ABBV, await full EPCORE DLBCL-2 data and disclosed commercial economics before assigning material value to the result. Look for event-driven upside at data release, but do not infer the split of potential value from the collaboration announcement.
• Use ESMO and the promised fourth-quarter colorectal updates as event dates, not automatic entry signals. No cross-company valuation or price data are supplied; avoid sizing a relative-value trade until trial details and current expectations are checked.